Journal article
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
Abstract
AIMS: We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding.
MATERIALS & METHODS: In total, 982 warfarin-treated patients from the RE-LY trial were studied.
Authors
Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Par G; Reilly P
Journal
Pharmacogenomics, Vol. 17, No. 13, pp. 1425–1439
Publisher
Taylor & Francis
Publication Date
8 2016
DOI
10.2217/pgs-2016-0061
ISSN
1462-2416